The largest database of trusted experimental protocols

Metformin

Metformin is a widely used oral antidiabetic medication that belongs to the biguanide class.
It is primarily employed in the treatment of type 2 diabetes, helping to lower blood glucose levels by reducing hepatic glucose production and increasing peripheral glucose uptake.
Metformin has also been investigated for its potential benefits in other conditions, such as polycystic ovary syndrome, gestational diabetes, and certain types of cancer.
Researchers continue to explore the optimal protocols and prodcuts for Metformin, with a focus on enhancing reproducibility and accuracy to support improved patient outcomes.
The PubCompare.ai platform offers advanced comparison tools to assist users in navigating the latest Metformin research, taking the guesswork out of their studies and elevating their work to new heights.

Most cited protocols related to «Metformin»

We designed algorithms for application to primary and secondary care data to establish incident diabetes cases. Our focus was on type 2 diabetes, given the age of UKB participants at recruitment. To assist generalisability to the UKB population, we restricted CPRD data to those on whom we had linked secondary care data, people aged 40–69 years on 1st January 2006, (to reflect age entry criteria for UKB) Primary care algorithms were derived based on four types of evidence: 1) Diabetes diagnostic codes (considered separately as any diagnostic code and the more specific C10E [type 1 diabetes] or C10F [type 2 diabetes] codes, these are a requirement for the Quality Outcomes Framework [QOF] system[14 (link)]), 2) Diabetes medication, (excluding those on metformin only as this has other prescribing indications e.g. pre-diabetes, polycystic ovarian syndrome and is therefore not wholly diabetes specific), 3) Hyperglycaemia on blood results (defined as HbA1c≥6.5% or 48 mmol/mol, or fasting/ random/ unspecified glucose≥11.1 mmol/l) and 4) Presence of diabetes process of care codes (restricted to those routinely recorded for QOF monitoring purposes, e.g. retinopathy screening, foot checks etc.). The threshold for glucose was chosen because primary care records frequently do not specify whether glucose is fasting or not, and we wished to avoid false positives from a non-fasting glucose in the 7.0–11.1 mmol/l range. Using CPRD and the linked Welsh UKB sub-cohort, we used an iterative approach, cross-tabulating evidence at each step, to determine the logical steps to include in the algorithm and in what order. We then applied the final incidence algorithm to both databases. For CPRD, we excluded prevalent diabetes according to pre-existing C10 diabetes-specific Read codes, and for the Welsh dataset, we removed all those with prevalent diabetes according to our UKB algorithm.
When developing the incidence algorithms intended for secondary care data, we defined incident diabetes type based on ICD-10 codes (E10 = type 1 diabetes, E11 = type 2 diabetes, E13/E14 = unspecified diabetes). Prevalent diabetes was excluded as above.
For both primary and secondary care incidence algorithms, we derived event dates by taking the mid-point between the last primary care consultation/ hospital admission without diabetes and the date of the first diabetes Read code/ ICD code/ diabetes medication/ hyperglycaemic blood test/ fifth process of care code. If there were no previous consultations or admissions, we used the UK Biobank inception date. The date of the first diabetes Read code/ ICD code/ diabetes medication/ hyperglycaemic blood test/ fifth process of care code will be available to researchers separately if they wish to calculate the event date in an alternative manner.
Full text: Click here
Publication 2016
BLOOD Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus, Non-Insulin-Dependent Diagnosis Foot Glucose Hematologic Tests Hyperglycemia Metformin Pharmaceutical Preparations Polycystic Ovary Syndrome Primary Health Care Retinal Diseases Secondary Care States, Prediabetic Substance Abuse Detection

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Diabetes Mellitus Ethics Committees, Research Metformin Minority Groups Placebos Racial Groups Racial Minorities Woman

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Adult Alcohol Use Disorder Antibodies, Antinuclear Autoimmune Chronic Hepatitis Child Ethanol Fibrosis Hemochromatosis Hepatitis B Hepatolenticular Degeneration Hypergammaglobulinemia Liver Diseases Metformin Necrosis Non-alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis Pioglitazone Placebos Primary Biliary Cholangitis SERPINA5 protein, human TimeLine Vitamin E Woman
We estimated simultaneous adherence to multiple medication classes for each patient by using the prescription-based adherence estimated for each class in 3 distinct ways (Figure 2). First, we calculated an average of the prescription-based PDC for each patient and then generated a group mean of these averages for the entire cohort. For example, for patients taking 2 classes of oral hypoglycemics, the PDC for each was calculated and then averaged, and this average was used to calculate the mean group PDC. Second, we calculated the number of days during which patients had at least 1 of their prescribed medications available to them beginning from the date they filled their first prescription for any oral hypoglycemic (ie, their earliest index date) until their latest prescription date for any of the medications they were using. For example, for a patient being treated with metformin and glyburide, the numerator of the adherence measure was the number of days during which he or she had either metformin or glyburide available. Third, we estimated the proportion of patients who had a prescription-based PDC of at least 80% for each medication they were using. For example, for patients treated with glyburide and metformin, each patient was considered adherent if his or her prescription-based PDC for each was at least 80%.
We repeated this process using interval-based adherence estimates. In this way, we determined adherence using 6 different methods (ie, 3 different techniques for each of the prescription-based and interval-based methods).
Publication 2009
Glyburide Hypoglycemic Agents Metformin Patients Pharmaceutical Preparations
Multivariable Cox regression analyses were adopted to assess the independent association between preadmission metformin use and 30-day mortality. An extended Cox model approach was used for different covariates adjusted models (22 (link)). Survival curves were plotted by Kaplan–Meier and log-rank analyses. Subgroup analyses were stratified by some relevant effect covariates.
Descriptive analysis was applied to all participants. Categorical variables were expressed as proportions (%). Continuous data were expressed as mean and standard deviation (SD) or median and interquartile range (IQR), as appropriate. Variables were compared using the chi-square tests (categorical variables) and One-Way ANOVA (normal distribution), Kruskal-Wallis (skewed distribution) test, respectively.
All the analyses were performed with the statistical software packages R 3.3.2 (http://www.R-project.org, The R Foundation) and Free Statistics software versions 1.1. A two-tailed test was performed and p < 0.05was considered statistically significant.
Full text: Click here
Publication 2021
Metformin neuro-oncological ventral antigen 2, human

Most recents protocols related to «Metformin»

The IraPEN's preventive actions are expected to reduce cardiovascular events. The relative risks (RRs) of these preventive actions and the medications that are used in the program were obtained from meta-analyses or randomized clinical trials (RCTs). By multiplying or adding up the RRs of different medications, there is a risk of effect overestimation, and a correction was made by using the formula below wherever multiple interventions were involved:
This equation has been developed based on a study that compared the effect of controlling the risk factors separately vs. controlling all of them simultaneously (15 (link)).
Based on the field interviews, it was clear which medications are used for each index cohort. Almost in all cases, angiotensin-converting enzyme (ACE) inhibitors are the first choice for hypertension treatment. Enalapril is the most prescribed one as monotherapy. Thiazides (diuretics) are the second choice followed by beta-blockers. In case the hypertension is not controlled by monotherapy instead of increasing the dose, the second drug is added. As recommended by guidelines, small doses of various classes of antihypertensive medications are more useful than a high dose of one (16 ). In general, the combination of ACE inhibitors and thiazide is the most common one. This pattern is aligned with Joint National Committee (JNC8) guidelines. Statins are prescribed for hyperlipidemia treatment. Among statins, Atorvastatin is the choice as it is one of the most potent ones. For diabetes, Metformin is started and increased to the maximum dose (2 g) and then the second medication that is Glibenclamide is added. Due to its potential harm and insufficient evidence of its efficacy, Aspirin was not recommended for primary prevention by PEN protocols. Therefore, Aspirin is not used in IraPEN as well. Here are the list of medications and their daily dosages which are used in IraPEN:
The unit price of each of these medications was derived from the Iranian Annual Pharma Statistics file. For the calculation of the intervention's effects, it is assumed that the adherence of individuals to the treatment is 100%. Table 3 lists the RRs of different interventions (medications) for CHD and stroke.
Full text: Click here
Publication 2023
Adrenergic beta-Antagonists Angiotensin-Converting Enzyme Inhibitors Antihypertensive Agents Aspirin Atorvastatin Cardiovascular System Cerebrovascular Accident Diabetes Mellitus Diuretics Enalapril Glyburide High Blood Pressures Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemia Joints Metformin PEN protocol Pharmaceutical Preparations Primary Prevention Selection for Treatment Thiazides
To mitigate risk of confounding, we assessed and adjusted for > 30 baseline covariates that were assessed in the 12-month period prior to and including the index date. These covariates included patient sociodemographics (e.g., age at medication initiation, biological sex, and race, calendar year), complications of diabetes (e.g., diabetic neuropathy, nephropathy, retinopathy), oral and injectable glucose lowering therapies (e.g., metformin, sulfonylureas, insulin), diagnosis of cardiovascular conditions (e.g., myocardial infarction, stroke, HF), and cardiovascular medication use (e.g., dispensing of β-blockers, loop diuretics, statins). Frailty status was ascertained using the claims based frailty index, and using a threshold of ≥ 0.25 to define frailty [23 (link)].
Propensity scores were estimated using a logistic regression that modelled the probability of initiating SGLT2i (exposure) versus a non-gliflozin medication (control) conditional on the baseline covariates. These propensity scores were then used to estimate stabilized inverse probability of treatment weights (IPTW) to account for imbalances in patient characteristics [24 (link)].
Full text: Click here
Publication 2023
Biopharmaceuticals Cardiovascular Agents Cardiovascular Diseases Cerebrovascular Accident Complications of Diabetes Mellitus Diabetic Neuropathies Diagnosis Glucose Hydroxymethylglutaryl-CoA Reductase Inhibitors Insulin Kidney Diseases Loop Diuretics Metformin Myocardial Infarction Patients Pharmaceutical Preparations Retinal Diseases Sodium-Glucose Transporter 2 Inhibitors Sulfonylurea Compounds
The analyses included six pivotal randomized, double-blind trials of dulaglutide 1.5 mg in participants with T2D that measured sitting SBP and DBP from vital sign data around the timeline of 6 months (week 24 to week 26). Five placebo-controlled studies were used to estimate the effects between dulaglutide 1.5 mg and placebo. AWARD-1 (NCT01064687), AWARD-5 (NCT00734474), AWARD-8 (NCT01769378), and AWARD-10 (NCT02597049) were phase 3, placebo-controlled trials which investigated the safety and glycemic efficacy of dulaglutide with various background glycemic therapies (Table 1). Ferdinand et al. (NCT01149421) was a phase 2, randomized, double-blind, placebo-controlled trial which evaluated BP and heart rate effects of dulaglutide vs. placebo in participants with T2D with and without hypertension and BP < 140/90 mmHg. In addition, AWARD-11 (NCT03495102) was a phase 3, non-placebo-controlled trial to evaluate safety and glycemic efficacy of dulaglutide 3.0 mg and 4.5 mg to dulaglutide 1.5 mg.

Study design for placebo-controlled trials included in the meta-analysis

ParametersAWARD-1AWARD-5AWARD-8AWARD-10AWARD-11Ferdinand et al
PhasePhase IIIPhase II/IIIPhase IIIPhase IIIPhase IIIPhase II
RandomizationRandomizedRandomizedRandomizedRandomizedRandomizedRandomized
BlindingBlindingDouble-blindDouble-blindDouble-blindDouble-blindDouble-blind
Primary EndpointA1cA1cA1cA1cA1c24-h SBP
Study Treatment Period52 weeks24 months24 weeks24 weeks52 weeks26 weeks
Last scheduled visit with PBO26 weeks6 months24 weeks24 weeks52 weeks (no PBO)26 weeks
Background therapy (Add-ons)Met + TZDMet monoSU monoSGLT2i with or without metforminMet monoStable OAM
Key inclusion/ exclusion criteria
 Age ≥ 18 years18–75 years ≥ 18 years ≥ 18 years ≥ 18 years ≥ 18 years
 T2D durationNA ≥ 6 monthsNANAfor ≥ 6 monthsNA
 A1c7.0–11.07.0–9.57.5–9.57.0–9.57.5–117–9.5
 BMI23–4525–40 ≤ 45 ≤ 45 ≥ 25NA
 MedicationStable OAMDiet & exercise / metformin and/or other OAMStable SUSGLT2i with or without metformin for ≥ 3 monthsStable metformin for ≥ 3 monthsOAM

BMI body mass index, NA not applicable for the study’s design, Met metformin, mono monotherapy, OAM oral antihyperglycemic medication, PBO placebo, SBP systolic blood pressure, SGLT2i sodium-glucose cotransporter-2 inhibitors, SU sulfonylurea, T2D type 2 diabetes, TZD thiazolidinediones

Full text: Click here
Publication 2023
Diabetes Mellitus, Non-Insulin-Dependent dulaglutide High Blood Pressures Hypoglycemic Agents Index, Body Mass inhibitors Metformin Pharmaceutical Preparations Placebos Rate, Heart Safety Signs, Vital SLC5A2 protein, human Sulfonylurea Compounds Systolic Pressure Therapeutics Thiazolidinediones TimeLine
A total of 508-week-old male C57BL6/J mice, including 40 db/db and 10 db/m mice, were purchased from Changzhou Cavens Laboratory Animal Co., Ltd [license key: SCXK (Su) 2016-0010, Jiangsu, China]. All experimental protocols in this research were approved by the Committee on the Ethics of Animal Experiments of the Jiangxi Normal University (Permission Number: JNU20210311-001). The breeding environment of mice was strictly controlled (25 ± 2°C, relative humidity 50 ± 5%, and 12/12 h diurnal cycle). After 1 week of adaptive feed, the 40 db/db mice were randomly divided into 5 groups: the diabetes group (Mod), the metformin group (250 mg/kg body weight per day, Met250), the low-dose group (100 mg/kg body weight per day, EAF100), the middle-dose group (250 mg/kg body weight per day, EAF250), and the high-dose group (400 mg/kg body weight per day, EAF400) and fed with D12451 during the period of drug administration. The non-diabetic mice (db/m) fed with D12450B only were used as the control group (Con). The drugs were dissolved in 5% Macrogol 400 solution; the Con and Mod groups were gavaged with a corresponding dose of 5% Macrogol 400 solution per day. The body weight and fast blood glucose (FBG) of all mice were measured weekly during the continuous administration for 8 weeks.
Full text: Click here
Publication 2023
Acclimatization Animals, Laboratory Blood Glucose Body Weight Diabetes Mellitus Humidity J 508 Males Metformin Mice, House Pharmaceutical Preparations polyethylene glycol 400
Dried Radix Alba Paeoniae was purchased from Anqing Chunyuan pharmacy in Anqing city, Anhui province, China on June 2021. Analytic-grade chloroform, ethyl acetate, and n-butanol and chromatographic-grade acetonitrile and formic acid were from Aladdin Reagent Int. (Shanghai, China). Metformin, acarbose, 1,1-diphenyl-2-picrylhydrazyl (DPPH), 2,2-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), α-glucosidase, and p-nitrophenyl-α-D-galactopyranoside (pNPG) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human hepatocellular carcinoma cells (HepG2) and culture media were purchased from the BeNa Culture Collection (Beijing, China). All other chemicals were of analytical grade and from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China).
Full text: Click here
Publication 2023
2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 4-nitrophenylgalactoside Acarbose acetonitrile alpha Glucosidase Butyl Alcohol Cells Chloroform Chromatography Culture Media diphenyl ethyl acetate formic acid Galactose Hepatocellular Carcinomas Homo sapiens Metformin Plant Roots Sulfonic Acids

Top products related to «Metformin»

Sourced in United States, Germany, China, United Kingdom, Sao Tome and Principe, Canada, Italy, Japan, France, Macao, Singapore, Switzerland, Mexico
Metformin is a laboratory compound used in research and development applications. It serves as a core compound for further chemical modifications and investigations. Metformin is widely utilized in the pharmaceutical industry and academic research settings.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, Germany, China, Sao Tome and Principe, United Kingdom, India, Japan, Macao, Canada, France, Italy, Switzerland, Egypt, Poland, Hungary, Denmark, Indonesia, Singapore, Sweden, Belgium, Malaysia, Israel, Spain, Czechia
STZ is a laboratory equipment product manufactured by Merck Group. It is designed for use in scientific research and experiments. The core function of STZ is to serve as a tool for carrying out specific tasks or procedures in a laboratory setting. No further details or interpretation of its intended use are provided.
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States, Germany, China, United Kingdom
Compound C is a lab equipment product manufactured by Merck Group. It is a chemical compound with a specific molecular structure and properties. The core function of Compound C is to serve as a research tool for scientific investigations, but its precise intended use is not provided in this factual and unbiased description.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
Sourced in United States, Germany
Metformin is a pharmaceutical compound commonly used as a laboratory reagent. It is a white, crystalline powder that is soluble in water. Metformin is classified as a biguanide and is a widely used drug for the treatment of type 2 diabetes.
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.

More about "Metformin"

Metformin is a widely used oral antidiabetic medication that belongs to the biguanide class.
This versatile drug is primarily employed in the treatment of type 2 diabetes, helping to lower blood glucose levels by reducing hepatic glucose production and increasing peripheral glucose uptake.
However, the applications of Metformin extend beyond just diabetes management.
Researchers have also investigated Metformin's potential benefits in other conditions, such as polycystic ovary syndrome (PCOS), gestational diabetes, and certain types of cancer.
The PubCompare.ai platform offers advanced comparison tools to assist users in navigating the latest Metformin research, taking the guesswork out of their studies and elevating their work to new heights.
Exploring the optimal protocols and products for Metformin is an ongoing area of research, with a focus on enhancing reproducibility and accuracy to support improved patient outcomes.
Synonymous terms like FBS (fetal bovine serum), STZ (streptozotocin), and Penicillin/streptomycin are often used in Metformin-related studies, while DMEM (Dulbecco's Modified Eagle Medium) and Compound C serve as related compounds.
The use of Streptomycin and DMSO (dimethyl sulfoxide) may also be encountered in Metformin research.
By leveraging the insights and tools provided by PubCompare.ai, researchers can navigate the vast landscape of Metformin-related literature, pre-prints, and patents, ensuring their work is informed by the latest developments and best practices.